期刊文献+

47例青斑血管炎临床分析 被引量:7

Clinical analysis of 47 cases of livedo vascniitis
原文传递
导出
摘要 目的探讨青斑血管炎患者的临床与病理特点。方法分析47例青斑血管炎患者临床资料,主要治疗措施为单纯抗凝,或抗凝联合糖皮质激素抗炎,或抗凝联合柳氮磺吡啶抗炎。结果临床表现为:皮损首先表现为瘀点或瘀斑、水肿伴胀痛,在此基础上出现点状坏死,逐渐出现虫蚀状溃疡,最后形成白色萎缩。组织病理:真皮浅层或伴真皮深层小血管壁纤维素样变性与管腔内血栓形成、受损血管周围可见稀疏淋巴细胞浸润;单纯抗凝组、抗凝联合糖皮质激素组及抗凝联合柳氮磺吡啶组的平均起效时间分别为(9.14±3.48)、(5.62±1.04)、(8.23±2.68)d,而疾病平均缓解时间分别为(2.57±1.41)、(4.06±1.51)、(5.64±1.32)个月。结论抗凝联合抗炎治疗青斑血管炎可能比单纯抗凝治疗起效更快,有利于控制复发。 Objective To assess the clinical and pathological feature of patients with livedo vasculitis. Methods Clinical data were collected from 47 patients with livedo vasculitis, and retrospectively analyzed. All the patients were classified into three groups according to treatment strategy: anticoagulation group, anticoagulation + corticosteroids group, and anticoagulation + sulfasalazine group. Results Clinically, livedo vasculitis usually began as petechia or ecchymosis, edema with distending pain, followed by spotty necrosis which subsequently evolved into vermiculated ulcers and, finally, atrophie blanche. Pathological features included fibrinoid degeneration of and thrombus formation in small vessel walls within the superficial or deep dermis, as well as a sparse lymphocytic infiltrate around the injured vessels. The average time to onset of action of administrated drugs was (9.14 ± 3.48), (5.62± 1.04) and (8.23 ± 2.68) days, and time to remission was (2.57 ± 1.41), (4.06 ±1.51) and (5.64 ± 1.32) months, in the anticoagulation group, anticoagulation + corticosteroids group and anticoagulation + sulfasalazine group, respectively. Conclusion Anticoagulation in combination with anti-inflammatory therapy appears to have a more rapid onset of action in the treatment of livedo vasculitis with a reduced recurrence rate compared with anticoagulation therapy alone.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2013年第9期630-632,共3页 Chinese Journal of Dermatology
关键词 青斑血管炎 抗凝药 抗炎药 病理学 Livedo vasculitis Anticoagulants Anti-inflammatory drugs Pathology
  • 相关文献

参考文献6

  • 1冯素英,靳培英.20例青斑血管炎患者的临床特点和治疗分析[J].中华皮肤科杂志,2006,39(10):571-573. 被引量:10
  • 2Toth C, Trotter M, Clark A, et al. Mononeuropathy muhiplex in association with livedoid vasculitis. Muscle Nerve, 2005, 28(5): 634-639.
  • 3Gan EY, Tang MB, Tan SH, et al. A ten-year retrospective study on livedo vasculopathy in Asian patients. Ann Acad Med Singapore, 2012, 41 ( 9 ): 400-406.
  • 4Ishbashi M, Miyamoto J, Nagasaka T, et al. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?. Am J Dermatopathol, 2009, 31 (3): 293-296.
  • 5Pitarch G, Rodriguez-Serua M, Torrijos A, et al. Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins. Acta Derm Venereol, 2005, 85(4): 374-375.
  • 6Criado PR, Rivitti EA, Sotto MN, et al. Livedoid vasculopathy: an intringuing cutaneous disease. An Bras Dermatol, 2011, 86 (5): 961-977.

二级参考文献6

  • 1齐焕英,金江,孙祎山,张建中.白色萎缩2例[J].中国皮肤性病学杂志,2004,18(11):700-700. 被引量:2
  • 2杜娟,朱铁君.白色萎缩1例[J].临床皮肤科杂志,1994,23(6):343-344. 被引量:9
  • 3黄正吉 邱丙森.节段性透明性血管炎26例分析[J].中华皮肤科杂志,1998,21(6):369-371.
  • 4Maessen-Visch MB,Koedam MI,Hamulyak K,et al.Atrophie blanche.Int J Dermatol,1999,38:161-172.
  • 5Ravat FE,Evans AV,Russell-Jones R.Response of livedoid vasculitis to intravenous immunoglobulin.Br J Dermatol,2002,147:166-169.
  • 6Acland KM,Darvay A,Wakelin SH,et al.Livedoid vasculitis:a manifestation of the antiphospholipid syndrome? Br J Dermatol,1999,140:131-135.

共引文献9

同被引文献38

  • 1冯素英,靳培英.20例青斑血管炎患者的临床特点和治疗分析[J].中华皮肤科杂志,2006,39(10):571-573. 被引量:10
  • 2Goerge T.Niedermolekulare heparin-therapie zur behandlungder livedovaskulopathie[J].Aktuelle Derm,2010(36):484-487.
  • 3Noda S,Asano Y,Yamazaki M,et al.Severe livedoid vasculopathy associated with antiphosphatidylserine-prothrombin complex antibody successfully treated with warfarin[J].Arch Dermatol,2011,147(5):621-623.
  • 4张凡,涂平,朱学骏.青斑样血管炎[J].临床皮肤科杂志,2007,36(12):803-804. 被引量:15
  • 5Gonzalez-Santiago TM, Davis MD. Update of management of connective tissue diseases: livedoid vasculopathy [J]. Dermatol Ther, 2012, 25( 1529-8019 (Electronic): 183-194.
  • 6Criado PR, Rivitti Ea Fau Sotto MN, Sotto Mn Fau Valente NYS, et al. Livedoid vasculopathy: an intringuing cutaneous disease[J]. Anais Brasileiros de Dermatologia, 2011, 86 (1806-4841 ( Electronic ): 961-977.
  • 7Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryoflbrinogenemia and hyperhomocysteinemia [J ]. Arch Dermatol, 2006, 142(0003-987X (Print): 75-78.
  • 8Di Giacomo TB, Hussein Tp Fau Souza DG, Souza Dg Fau Criado PR, et al. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs: a prospective study [ J ]. J Eur Acad Dermatol Venereol, 2010, 24( 1468-3083 (Electronic): 1340-1346.
  • 9Khenifer S, Thomas L, Balme B, et al. Livedoid vasculopathy: thrombotic or inflammatory disease? [J]. Clin Exp Dermatol, 2010, 35(7 ): 693-698.
  • 10Khenifer S, Thomas L, Balme B, et al. Livedoid vasculiltis associated with a double heterozygous Factor V Leiden and prothrombin G20210A gene mutations [J]. Clin Exp Dermatol, 2009, 34(8): e811-e813.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部